[M1] Enzyme Methodologies Flashcards

(385 cards)

1
Q

Liver enzymes is also called as

A

Hepatic enzymes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Enumerate the Liver Enzymes

A

Alkaline Phosphatase
Aspartate Aminotransferase
Alanine Aminotransferase
Gamma-Glutamyltransferase
5’-Nucleotidase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

ALP

A

ALKALINE PHOSPHATASE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

E.C OF ALP

A

E.C. 3.1.3.1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Catalyze the hydrolysis of phosphomonoesters at an alkaline pH (9.0-10.0)

A

ALKALINE PHOSPHATASE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

ALP catalyzes the hydrolysis of _________________ at an (acidic/alkaline) pH (_____________)

A

ALP

phosphomonoesters
alkaline
9.0-10.0

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Common name of ALP

A

alkaline orthophosphoric monoester phosphohydrolase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

ALP

Function:
remove (organic/inorganic) phosphate from an (organic/inorganic) phosphate ester with the concomitant production of ___________

A

inorganic
organic
alcohol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

T/F: ALP is a non-specific enzyme

A

T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Activators of ALP

A

Mg2+
Co2+
Mn2+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

inhibitors of ALP

A

phosphate
borate
oxalate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

ALP is useful for evaluation of ___________ and ________ disorders

A

hepatobiliary
bone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

RF of ALP in 20-50 MALE

A

53-128 U/L

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

RF of ALP in 20-50 FEMALE

A

42-98 U/L

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

RF of ALP in ≥60 MALE

A

56-119 U/L

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

RF of ALP in ≥60 FEMALE

A

53-141 U/L

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

RF of ALP in 4-15

A

54-369 U/L

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the major ALP isoenzymes

A

Liver ALP
Bone ALP
Placental ALP
Intestinal ALP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Half life of Liver ALP

A

3 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Half life of Bone ALP

A

1 day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Half life of Placental ALP

A

7 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Half life of Intestinal ALP

A

1 day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Rank the ALP isoenzymes from most ANODAL to least ANODAL

A
  1. Liver ALP
  2. Bone ALP
  3. Placental ALP
  4. Intestinal ALP
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Rank the ALP isoenzymes from most CATHODAL to least CATHODAL

A
  1. Intestinal ALP
  2. Placental ALP
  3. Bone ALP
  4. Liver ALP
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Rank the ALP isoenzymes from most heat stable to least heat stable
1. Placental ALP 2. Intestinal ALP 3. Liver ALP 4. Bone ALP
26
Rank the ALP isoenzymes from most heat-labile to least heat-labile
1. Bone ALP 2. Liver ALP 3. Intestinal ALP 4. Placental ALP
27
inhibitor of Liver ALP
Levamisole
28
inhibitor of Bone ALP
Levamisole & 3M urea
29
Inhibitor of Placental ALP
Phenylalanine
30
Inhibitor of Intestinal ALP
Phenylalanine
31
BEFORE HEAT Placental ALP Liver ALP Bone ALP
100% 100% 100%
32
AFTER HEAT Placental ALP Liver ALP Bone ALP
100% >20% <20%
33
Heat Fractionation/ Stability Test is measured @ ____ for ____ minutes
56°C 10 minutes
34
T/F: ALP isoenzymes are NOT measured before and after heating
F; Measured before and after heating
35
separates liver and bone ALP
Neuraminidase Wheat Germ Lectin
36
Steps in Heat Fractionation/ Stability Test
1. Measure ALP 2. Heat sample @ 56°C for 10 minutes 3. Measure ALP
37
Heating sample @ 56°C for 10 minutes significance
To inactivate other isoenzymes
38
Abnormal ALP isoenzyme associated with neoplasms or cancer
Carcinoplacental ALPs
39
Carcinoplacental ALPs Abnormal ALP isoenzyme associated with __________ or _________
neoplasms cancer
40
2 types of Carcinoplacental ALPs
Regan ALP Nagao ALP
41
Detected in gynecological CA (ovarian, breast), lung CA, and colon CA.
Regan ALP
42
Regan ALP Detected in ________ (ovarian, breast), ___ CA, and ____ CA.
gynecological CA lung CA colon CA
43
Migrates to the same position as the Bone ALP
Regan ALP
44
Regal ALP migrates to the same position as ___________
Bone ALP
45
Most heat stable ALP isoenzyme
Regan ALP
46
T/F: Regan ALP is more heat stable than placental ALP
T
47
Regan ALP is stable @ ______for ____minutes
65°C 30
48
Inhibitor of Regan ALP
phenylalanine
49
Detected in metastatic carcinoma of pleural surfaces, and adenocarcinoma of pancreas and bile ducts
Nagao ALP
50
Nagao ALP Detected in _______________ of pleural surfaces, and ____________ of pancreas and bile ducts
metastatic carcinoma adenocarcinoma
51
Nagao ALP Detected in metastatic carcinoma of _________________, and adenocarcinoma of _______ and _________
pleural surfaces pancreas and bile ducts
52
Variant of Regan ALP
Nagao ALP
53
Inhibitor of Nagao ALP
phenylalanine L-Leucine
54
Method of Analysis for ALP
Bowers and McComb
55
A continuous monitoring method allowing calculation of ALP activity based on the molar absorptivity of _________________
BOWERS AND MCCOMB p-nitrophenol
56
The most specific method; IFCC recommended method
Bowers and McComb
57
Enumerate the Other Methodologies for ALP
1. Bodansky 2. Shinowara 3. Jones 4. Reinhart 5. King and Armstrong 6. Bessy, Lowry, and Brock 7. Bowers and McComb 8. Huggins and Talalay 9. Moss 10. Klein, Babson and Read
58
Substrate for 1. Bodansky 2. Shinowara 3. Jones 4. Reinhart
Beta-Glycerol Phosphate
59
End Product for 1. Bodansky 2. Shinowara 3. Jones 4. Reinhart
Inorganic phosphate + glycerol
60
Substrate for King and Armstrong
Phenylphosphate
61
End product for King and Armstrong
Phenol
62
Substrate for 6. Bessy, Lowry, and Brock 7. Bowers and McComb
p-nitrophenyl phosphate
63
End product for 6. Bessy, Lowry, and Brock 7. Bowers and McComb
p-nitrophenol/ yellow nitrophenoxide ion
64
Substrate for Huggins and Talalay
Phenolphthalein phosphate
65
End product for Huggins and Talalay
Phenolphthalein red
66
Substrate for Moss
Alpha-naphthol phosphate
67
End product for Moss
Alpha-naphthol
68
Substrate for Klein, Babson, and Read
Buffered phenolphthalein phosphate
69
End product for Klein, Babson, and Read
Free phenolphthalein
70
False Increase of ALP
Hemolysis Diet (Fatty meals) Stored at low temperature (4°C)
71
FALSE INC. IN ALP Hemolysis - ALP in RBC is ___ more concentrated than serum or plasma
6x
72
FALSE INC. IN ALP Diet (fatty meals) - ALP is ____ higher
25%
73
Diagnostic Significance of ALP ALP - #1 marker in ______________
obstructive jaundice
74
Increased ALP
● Osteitis deformans ● Obstructive Jaundice ● Osteomalacia ● Rickets ● Osteoblastic bone tumors ● Sprue ● Hyperparathyroidism ● Hepatitis and Cirrhosis
75
Osteitis deformans is also known as
“Paget’s disease”
76
AST
ASPARTATE AMINOTRANSFERASE
77
E.C of ASPARTATE AMINOTRANSFERASE
E.C. 2.6.1.1
78
Old name of ASPARTATE AMINOTRANSFERASE
Serum Glutamic Oxaloacetate Transaminase
79
ASPARTATE AMINOTRANSFERASE Catalyze the transfer of amino groups between _________ (substrate) and ___________
aspartate a-ketoacids
80
ASPARTATE AMINOTRANSFERASE Catalyze the transfer of amino groups between aspartate (substrate) and a-ketoacids with the formation of ________ and ___________
oxaloacetate glutamate
81
ASPARTATE AMINOTRANSFERASE Coeznyme
Pyridoxal phosphate
82
ASPARTATE AMINOTRANSFERASE Major Tissue Source
Cardiac tissues liver and skeletal muscle
83
ASPARTATE AMINO TRANSFERASE RR
5-35 U/L
84
ASPARTATE AMINOTRANSFERASE Isozenzymes
Cytoplasmic AST Mitochondrial AST
85
Predominant in the circulation of a healthy individual
Cytoplasmic AST
86
Method of Analysis for AST
Karmen Method
87
Karmen Method is what type of enzymatic method
Coupled enzymatic method
88
Indicator enzyme for Karmen method
Malate dehydrogenase (MD)
89
KARMEN METHOD (AST) It monitors the (increase/decrease) in absorbance at _____ nm
decrease 340
90
KARMEN METHOD (AST) Storage: stable for ____ days at __________
3-4 refrigerated temp.
91
Variables for Karmen Method
Hemolysis
92
Hemolysis in Karmen Method results in false (increase/decrease) up to ___
increase 10x
93
Exhibits highest level AST
Acute Hepatocellular Disorder
94
ALT
ALANINE AMINOTRANSFERASE
95
E.C OF ALANINE AMINOTRANSFERASE
● E.C 2.6.1.2
96
old name for Alanine Aminotransferase
Serum Glutamic Pyruvic Transaminase
97
ALANINE AMINOTRANSFERASE Catalyze transfer of amino group between _________ (substrate) and ______________
alanine a-ketoglutarate
98
ALANINE AMINOTRANSFERASE is significant in the evaluation of what disorders
Hepatic disorders
99
ALANINE AMINOTRANSFERASE (ALT) Coenzyme
Pyridoxal phosphate
100
ALANINE AMINOTRANSFERASE (ALT) Major Tissue Source
Liver
101
ALANINE AMINOTRANSFERASE (ALT) RR
7-45 U/L
102
Method of Analysis for ALANINE AMINOTRANSFERASE (ALT)
1. Coupled Enzymatic Method
103
ALT Indicator Enzyme for Coupled Enzymatic Method
Lactate Dehydrogenase (LDH)
104
Coupled Enzymatic Method (ALT) The change in absorbance at ______ nm measured ________________ is directly proportional to ALT activity (pH _________).
340 continuously 7.3-7.8
105
Coupled Enzymatic Method (ALT) Storage
3-4 days at 4°C
106
T/F: Hemolysis does NOT affect ALT
True
107
Increase Aminotransferases (AST, ALT)
1. Toxic Hepatitis 2. Acute Myocardial Infarction (AST) 3. Wolff-Parkinson White Syndrome 4. Trichinosis (AST) 5. Chronic alcoholism 6. Dermatomyositis 7. Hepatic cancer 8. Reye’s Syndrome 9. Viral Hepatitis 10. Muscular dystrophy (AST) 11. Acute pancreatitis (AST)
108
Which disorders/diseases causes Increase in AST only
Acute Myocardial Infarction (AST) Trichinosis (AST) Muscular dystrophy (AST) Acute pancreatitis (AST)
109
Acute Myocardial Infarction (AST) Rise Peak Normal
6-8 hours 24 hours within 5 days
110
Trichinosis is caused by
Trichinella spiralis
111
unknown source in GGT is caused by pancreas
Acute pancreatitis
112
AST/ALT ratio
DE RITIS RATIO
113
Used to differentiate the cause of hepatic disorder
DE RITIS RATIO
114
DE RITIS RATIO >1: __________
non-viral cause
115
DE RITIS RATIO <1: __________
viral
116
GGT
GAMMA-GLUTAMYLTRANSFERASE
117
E.C of GAMMA-GLUTAMYLTRANSFERASE
E.C. 2.3.2.2
118
GAMMA-GLUTAMYLTRANSFERASE catalyzes ____________________
transpeptidation
119
The transfer of ɣ-glutamyl residue from ɣ-glutamyl peptides to amino acids, water and other peptides
transpeptidation
120
Used for diagnosis of hepatobiliary disorders and alcoholism
GAMMA-GLUTAMYLTRANSFERASE (GGT)
121
GAMMA-GLUTAMYLTRANSFERASE (GGT) is sed for diagnosis of _____________ and _____________
hepatobiliary disorders alcoholism
122
Useful for differentiating source of serum ALP elevation
GAMMA-GLUTAMYLTRANSFERASE (GGT)
123
LIVER DISORDER ALP GGT
Increased Increased
124
BONE DISEASE ALP GGT
Increased Normal
125
Critical for the intracellular maintenance of reduced glutathione
GAMMA-GLUTAMYLTRANSFERASE (GGT)
126
GAMMA-GLUTAMYLTRANSFERASE (GGT) Tissue source
Liver (epithelial cell lining of biliary ducts and bile canalicular) Kidneys Brain Pancreas, Intestine Prostate.
127
Method of Analysis for GAMMA-GLUTAMYLTRANSFERASE (GGT)
Szasz Assay
128
Method for Szasz Assay
Fixed-point or continuous monitoring
129
Szasz Assay Substrate
γ-glutamyl-p-nitroanilide
130
Szasz Assay End product
p-nitroaniline
131
Szasz Assay wavelength
405-420 nm
132
Szasz Assay Preferred specimen
Serum EDTA Plasma
133
Szasz Assay Storage:
4°C (1 week) -20°C (1 month)
134
Other Method for GGT
Rosalki and Tarrow, Orlowski
135
T/F; GGT is not effected by hemolysis
T
136
Why is GGT not affected by hemolysis?
GGT is not found in RBC
137
GGT RR: Male
6-55 U/L
138
GGT RR: female
5-38 U/L
139
Most sensitive marker of acute alcoholic hepatitis
GAMMA-GLUTAMYLTRANSFERASE (GGT)
140
Normal levels in patients with bone disease and during pregnancy
GAMMA-GLUTAMYLTRANSFERASE (GGT)
141
GGT Normalize: ___ weeks after consumption
2-3
142
5’N
5’-NUCLEOTIDASE
143
E.C. of 5'-NUCLEOTIDASE
E.C. 3.1.3.5
144
5'-NUCLEOTIDASE Other name
5’ ribonucleotide phosphohydrolase
145
A phosphoric monoester hydrolase reacting only on nucleoside-5’-phosphates (_______, __________) releasing (inorganic/organic) phosphate
5'-NUCLEOTIDASE AMP adenylic acid inorganic
146
5'-NUCLEOTIDASE Major Source
Liver
147
Marker of hepatobiliary disease and infiltrative lesions of the liver
5'-NUCLEOTIDASE
148
5'-NUCLEOTIDASE Marker of _____________ and ____________________ of the liver
hepatobiliary disease infiltrative lesions
149
Secondary Marker for Obstructive Jaundice
5'-NUCLEOTIDASE
150
Method for 5'-NUCLEOTIDASE
Dixon & Purdon Campbell Belfield & Goldberg
151
Method for 5'-NUCLEOTIDASE
Dixon & Purdon Campbell Belfield & Goldberg
152
5'-NUCLEOTIDASE RR
0-1.6 U/L
153
5'-NUCLEOTIDASE Storage
4°C (4 days) -20°C (4 months)
154
Enumerate the Pancreatic Enzymes
1. Amylase 2. Lipase
155
AMS
Amylase
156
E.C for Amylase
E.C. 3.2.1.1
157
AMYLASE Other name
alpha-1,4-glucan-4-glucohydrolase
158
AMYLASE Catalyzes the hydrolysis of __________________ in polysaccharides (_____, _____)
𝛂-1,4-glycosidic bonds starch, glycogen
159
Earlier pancreatic marker
Amylase
160
Smallest enzyme (freely filtered by the _________)
AMYLASE glomerulus
161
AMYLASE Activators
Calcium, Chloride
162
AMYLASE Major Tissue Source
Pancreas (acinar cells) Salivary Glands
163
AMYLASE (AMS) RR; Serum
28-100 U/L
164
AMYLASE (AMS) RR; Urine
1-15 U/h
165
Enumerate the isoenzymes of Amylase
1. S-type/Ptyalin/Salivary 2. P-type / Amylopsin / Pancreatic
166
↑ parotitis/mumps
1. S-type/Ptyalin/Salivary
167
The most anodal AMY isoenzyme
1. S-type/Ptyalin/Salivary
168
S-type/Ptyalin/Salivary is secreted by __________________
salivary glands
169
Inhibitor of S-type/Ptyalin/Salivary (inhibits activity of salivary glands)
Wheat Germ Lectin
170
↑ in acute pancreatitis
P-type / Amylopsin / Pancreatic
171
the most predominant subtype of P-type / Amylopsin / Pancreatic
P3
172
● Secreted by the pancreas and also by the fallopian tube & lungs
P-type / Amylopsin / Pancreatic
173
T/F: In the laboratory, we measure the Total Amylase
TRUE
174
Specimen for Amylase
Serum, Heparinized Plasma
175
Substrate for Amylase
Starch
176
Enumerate the different Method of Analysis of Amylase
1. Saccharogenic 2. Amyloclastic 3. Chromogenic 4. Coupled-Enzyme
177
AMYLASE Classic reference method
Saccharogenic
178
It measures the amount of __________ produced by the hydrolysis of ______ by the usual glucose method
SACCHAROGENIC reducing sugars starch
179
Enumerate the glucose methods used in Saccharogenic
Hexokinase Glucose oxidase
180
Glucose methodology reference method
Hexoklnase
181
End product for Saccharogenic
Glucose
182
AMYLASE inverse method
Amyloclastic
183
It measures decrease in starch substrate
Amyloclastic
184
Amyloclastic Substrates are coupled with_____
iodine
185
Iodine + Starch = _____________
Dark-blue color
186
Why Dark Blue Color in Amyloclastic?
e iodine is trapped within the structure of the starch
187
T/F: In amyloclastic, decrease in color is proportional to AMS activity
T
188
Measures the formation of soluble starch fragments coupled with chromogenic dyes.
Chromogenic
189
Color intensity is proportional to AMS activity
Chromogenic
190
Measured amylase activity by a continuous-monitoring/kinetic technique.
Coupled-Enzyme
191
Substrate for Couple-Enzyme (Amylase)
Starch
192
Wavelength for Couple-Enzyme (Amylase)
340 nm
193
pH for Couple-Enzyme (Amylase)
6.9
194
Storage for Couple-Enzyme (Amylase)
Room temp (1 week) 4°C (2 months)
195
False Decrease in AMS
● Ca2+ Chelating Anticoagulant ● Triglycerides
196
False Increase in AMS
● Morphine, other opiates
197
amylase bound to immunoglobulin
Macroamylasemia
198
asymptomatic amylasemia
Macroamylasemia
199
In Macroamylasemia, (increase/decrease) serum AMS & (increase/decrease) N Urine AMS
Increase Decrease
200
↑ serum AMS & ↑ urine AMS
Hyperamylasemia
201
Amylase/Creatinine Ratio: Normal
1-4% (0.01-0.04)
202
Amylase/Creatinine Ratio: Acute Pancreatitis
>4%-15%
203
LPS
Lipase
204
E.C of Lipase
E.C. 3.1.1.3
205
LIPASE Other name
Triacylglycerolacylhydrolase
206
Catalyzes hydrolysis of glycerol esters of complex lipids to produce ___________ and ________.
LIPASE alcohol fatty acid.
207
Catalyzes partial hydrolysis of ________ to________________, with production of long-chain fatty acids.
LIPASE dietary TAG 2-monoglyceride intermediate
208
More pancreatic specific
LIPASE
209
LIPASE Cofactor
Colipase (coenzyme) Bile salts
210
LIPASE Major Tissue Source
Pancreas
211
LIPASE RR
<38 U/L
212
Method of Analysis for Lipase Specimen
Serum
213
Method of Analysis for Lipase Storage
room temp (1 week) 4°C (3 weeks)
214
Method of Analysis for Lipase Interferences
Hemolysis
215
Enumerate the Methods for Lipase
1. Cherry-Crandall 2. Tietz 3. Peroxidase Coupling
216
Substrate for Cherry-Crandall and Tietz
50% Olive oil (Triolein)
217
Titrating Agent for Cherry-Crandall and Tietz
0.4N NaOH
218
Indicator for Cherry-Crandall
Phenolphthalein
219
Indicator for Tietz
Thymolphthalein + Veronal
220
Endpoint for Cherry-Crandall and Tietz
Fatty Acids (Oleic acid)
221
End color of Cherry-Crandall
Pink
222
End color of Tietz
Blue
223
Most commonly used method (LPS)
Peroxidase Coupling
224
Does not use 50% olive oil (LPS)
Peroxidase Coupling
225
most specific pancreatic marker
Lipase
226
In chronic pancreatitis: → _____________ are destroyed → Loss of_____ and _____
Acinar cells AMS and LPS
227
AMYLASE Rise Peak Normalize
5-8 HOURS 24 HOURS 3-5 DAYS
228
LIPASE Rise Peak Normalize
4-8 HOURS 24 HOURS 8-14 DAYS
229
Enumerate the Cardiac Markers
1. Creatine Kinase 2. Lactate Dehydrogenase
230
CK
Creatine Kinase
231
E.C for Creatine Kinase
● E.C. 2.7.3.2
232
CREATINE KINASE Other Name
ATP-Creatine-N-phosphotransferase
233
Catalyzes phosphorylation of creatine to form _____________
CREATINE KINASE creatine phosphate.
234
Involved in the storage of high-energy creatine phosphate in ___________
CREATINE KINASE muscle cells
235
contains two subunits
CREATINE KINASE Dimeric Molecule
236
2 subunits of CREATINE KINASE
→ M subunit (Muscle) → B subunit (Brain)
237
CREATINE KINASE Major Tissue Source
brain muscles (smooth, skeletal, cardiac)
238
CREATINE KINASE RR: Male
46-171 U/L
239
CREATINE KINASE RR: Female
35-145 U/L
240
CREATINE KINASE RR: CK-MB
<5% of total CK
241
Enumerate the Normal Isoenzymes of Creatine Kinase
CK-BB CK-MB CK-MM
242
Rank the CK isoenzymes from most ANODAL to least ANODAL
1. CK-BB 2. CK-MB 3. CK-MM
243
Rank the CK isoenzymes from most CATHODAL to least CATHODAL
1. CK-MM 2. CK-MB 3. CK-BB
244
Brain type CK Isoenzyme
CK-BB
245
Hybrid type CK Isoenzyme
CK-MB
246
Muscle type CK Isoenzyme
CK-MM
247
Dominant in brain, intestines, and smooth muscles
CK-BB
248
CK-BB is dominant in:
brain intestines smooth muscles
249
Present in significant concentration in the cardiac muscles
CK-MB
250
CK-MB is present in significant concentration in the ___________________
cardiac muscles
251
Abundantly present in striated muscles
CK-MM
252
CK-MM is abundantly present in _________
striated muscles
253
Rarely found in Serum
CK-BB
254
Why is CK-BB rarely found in serum?
it cannot pass through the blood-brain barrier
255
Serodiagnostic tool for AMI
CK-MB
256
Major Isoenzyme in normal individual (______)
CK-MM 94-100%
257
Useful Non-Specific Tumor Marker
CK-BB
258
RV of CK-MB
<5% of Total CK
259
Myocardial Damage/AMI:
● Elevated CK-MB ● >6 of Total CK
260
earliest enzymatic cardiac marker
CK-MB
261
increased CREATINE KINASE
1. Acute Myocardial Infarction 2. Duchenne-type Muscular Dystrophy 3. Rhabdomyolysis 4. Cerebrovascular Accident 5. Seizures 6. Nerve Degeneration 7. CNS Shock 8. Hypothyroidism 9. Malignant Hyperpyrexia 10. Reye’s Syndrome
262
Highest elevation of total CK
Duchenne-type Muscular Dystrophy
263
Method of Analysis for CK Specimen
Serum Heparinized Plasma
264
Inhibitor of sulfhydryl group oxidation
→ N-acetylcysteine → Mercaptoethanol → Thioglycerol → Dithiothreitol
265
T/F: Serum activity in CK is stable
FALSE; VERY UNSTABLE
266
Why is serum in CK very unstable?
because it is easily be inactivated by sulfhydryl group by oxidation
267
Variables for CK
Hemolysis Light Non-heparinized Anticoagulant Physical Activity IM Injection
268
VARIABLES FOR CK Hemolysis hgb level
>320 mg/L HGB
269
Total CK in Hemolysis is falsely elevated due to ______________ (enzyme) that is present in RBC
Adenylate kinase
270
To prevent false elevation because of adenylate kinase, add __________________
Adenosine monophosphate
271
Why is light a variable in CK
because CK is inactivated if exposed to light
272
Methods for CK
1. Tanzer-Gilvarg Assay 2. Oliver-Rosalki Method
273
Methods for CK Forward/Direct Method
1. Tanzer-Gilvarg Assay
274
Tanzer-Gilvarg Assay is coupled with _______________________________________________
pyruvate kinase-lactate dehydrogenase-NADH system
275
Tanzer-Gilvarg Assay Optimal pH
9.0
276
Tanzer-Gilvarg Assay Wavelength
340 nm
277
Methods for CK Reverse/indirect Method
Oliver-Rosalki Method
278
Most commonly performed method for CK
Oliver-Rosalki Method
279
Oliver-Rosalki Method is couple with _______________________________________________________
Hexokinase-Glucose-6- Phosphate-Dehydrogenase-NADP system
280
Oliver-Rosalki Method Optimal pH
6.8
281
Oliver-Rosalki Method Wavelength
340 nm
282
LDH
Lactate Dehydrogenase
283
E.C of Lactate Dehydrogenase
E.C. 1.1.1.27
284
Catalyze the interconversion (reversible) of ________ and __________
LACTATE DEHYDROGENASE lactic acid pyruvic acid
285
LDH Coenzyme
NAD+
286
LDH Inhibitor
Ethylenediamine tetraacetic acid (EDTA)
287
contain A-peptide or M-peptide unit
LACTATE DEHYDROGENASE Tetrametic Molecule
288
● Widely distributed
LACTATE DEHYDROGENASE (LDH)
289
LDH Highest Activity
Heart RBCs skeletal muscles
290
LDH RV
125-220 u/L
291
Enumerate the LDH Isoenzymes
LD 1 LD 2 LD 3 LD 4 LD 5 LD 6
292
Most predominant LDH isoenzyme
LD 2
293
increased in pulmonary involvement and various carcinomas
LD3
294
LD3 is increased in ______________ and _____________________
pulmonary involvement various carcinomas
295
LDH Isoenzyme Seen in muscular injuries
LD 4
296
LD 6 a.k.a
Alcohol dehydrogenase
297
Present in Arteriosclerotic cardiovascular failure
LD 6
298
LD6 is present in _________________________
Arteriosclerotic cardiovascular failure
299
SUBUNITS LD 1 LD 2 LD 3 LD 4 LD 5 LD 6
HHHH HHHM HHMM HMMM MMMM none
300
Tissue source of LD 1
Heart, RBC
301
Tissue source of LD 2
Heart, RBC
302
Tissue source of LD 3
Liver Spleen, Lymphocytes Pancreas
303
Tissue source of LD 4
Liver
304
Tissue source of LD 5
Skeletal muscle
305
Percentage based on Total LDH LD 1
14-26%
306
Percentage based on Total LDH LD 2
29-39%
307
Percentage based on Total LDH LD 3
20-26%
308
Percentage based on Total LDH LD 4
8-16%
309
Percentage based on Total LDH LD 5
6-16%
310
used as tumor markers
LD 2 LD 3 LD 4
311
LD2, LD3, LD4 -used as tumor markers for:
→ acute leukemia → germ cell tumor → breast cancer → lung cancer
312
Most to least dominant cases of: (Descending Order) Normal Pattern
LD 2>1>3>4>5
313
Method of Analysis LDH Specimen
Serum
314
Method of Analysis LDH Substrate
→ Lactate → Pyruvate → α-hydroxybutyrate (LD1)
315
Method of Analysis LDH Storage: Total LD
25°C (48 hours)
316
Method of Analysis LDH Storage: LD isoenzymes
25°C (24 hours)
317
Variables for LDH
→ Plasma specimen → Hemolysis → Cold storage
318
Plasma specimen and Hemolysis in LDH causes false (increase/decrease) because of the presence of ____________
increase plaelets
319
Cold Storage of LDH causes false (increase/decrease) in _____ and _____
Decrease LD 4 and LD 5
320
Enumerate the methods used in LDH
1. Wacker Method 2. Wrobleuski La Due
321
Method of Analysis LDH Forward/Direct Method
Wacker Method
322
Method of Analysis (LDH)\ Most commonly used method
Wacker Method
323
pH in Wacker Method
8.3-8.9
324
Wavelength in Wacker Method
340 nm
325
Method of Analysis LDH Reverse/Indirect Method
Wrobleuski La Due
326
Wrobleuski La Due is ____ the rate of forward method
thrice
327
● Preferred Method for Dry-Slide Technology
Wrobleuski La Due
328
Example of Dry-Slide Techbology
Vitros Analyzer
329
Uses less costly cofactor and it has a smaller specimen volume requirement
Wrobleuski La Due
330
Wrobleuski La Due pH
7.1-7.4
331
Increased LDH
1. Acute Myocardial Infarction 2. Hemolytic anemia 3. Pernicious anemia 4. Pulmonary infarction 5. Muscle dystrophy 6. Hepatic carcinoma, toxic hepatitis, cirrhosis, viral hepatitis 7. Blood transfusion 8. Pneumocystis jirovecii infection
332
INCREASED LDH Acute Myocardial Infarction exhibits what type of pattern
→ Flipped pattern → LD 1>2>3>4>5
333
INCREASED LDH Pulmonary Infarction exhibits what pattern
LD 3>4>2>1>5
334
INCREASED LDH Muscle dystrophy what pattern
LD 5>4>3>2>1
335
Which disorders/diseases in Increased LDH exhibits increased LD 4
Hepatic carcinoma, toxic hepatitis, cirrhosis, viral hepatitis
336
__ & __ = LD is increased but normalize after ______
6 and 7 24 hours
337
T/F: Increase in Total LDH is insignificant
T
338
Why is an increase in Total LDH insignificant?
because LDH is present almost virtually in cells
339
Acute Myocardial infarction ______ of total CK ______
>6% 1:20:0
340
Acute Myocardial infarction Enumerate the Enzymes involved
Aspartate Aminotransferase Creatine Kinase-MB Lactate Dehydrogenase
341
ACUTE MYCOCARDIAL INFARCTION Enzyme not liver specific
Aspartate aminotransferase
342
ACUTE MYOCARDIAL INFARCTION Enzyme cardiac specific
Creatine Kinase-MB
343
ASPARTATE AMINOTRANSFERASE Rise Peak Normalize
6-8 hours 24 hours Within 5 days
344
CREATINE KINASE-MB Rise Peak Normalize
4-8 hours ' 12-24 hours 48-72 hours
345
LACTATE DEHYDROGENASE Rise Peak Normalize
12-24 hours 48-72 hours After 10-14 days
346
Enumerate the other Clinically Significant Enzymes
1. Acid Phosphatase
347
ACP
Acid Phosphatase
348
E.C of ACID PHOSPHATASE
E.C. 3.1.3.2
349
ACID PHOSPHATASE Other name
Acid orthophosphoric monoester phosphohydrolase
350
Catalyze the hydrolysis of phosphomonoesters at an acidic pH
ACID PHOSPHATASE (ACP)
351
ACID PHOSPHATASE Major Tissue Source
Prostate
352
Useful for evaluation of metastatic-prostatic carcinoma
ACID PHOSPHATASE (ACP)
353
ACID PHOSPHATASE (ACP) i useful for evaluation of _____________________
metastatic-prostatic carcinoma
354
ACID PHOSPHATASE TOTAL ACP RR: Male
2-5-11.7 U/L
355
ACID PHOSPHATASE PROSTATIC ACP RR: Male
0.2-5.0 U/L
356
ACID PHOSPHATASE TOTAL ACP RR: Female
0.3-9.2 U/L
357
ACID PHOSPHATASE PROSTATIC ACP RR: Female
0.0-0.8 U/L
358
T/F: Total ACP is measured in the laboratory
True
359
Method of Analysis (ACP) Specimen
Serum
360
Method of Analysis ACP Substrates
Thymolphthalein monophosphate α-naphthyl phosphate
361
Substrate to use in ACP for end-point methods
Thymolphthalein monophosphate
362
Specific substrate for prostatic ACP
Thymolphthalein monophosphate
363
ACP substrate for continuous monitoring methods/kinetic assay
α-naphthyl phosphate
364
Methods of Analysis ACP INHIBITORS
L-Tartrate 2% formaldehyde, cupric sulfate solution
365
Inhibitor in ACP that inhibits prostatic ACP
L-Tartrate
366
Inhibitor in ACP that also Inhibit lysosomal ACP
L-Tartrate
367
Inhibitor in ACP that inhibits RBC ACP/TRAP
2% formaldehyde, cupric sulfate solution
368
Method of Analysis ACP Storage
Frozen Acidified
369
ACP is acidified in what pH
< pH of 6.5
370
When ACP is acidified, ACP is stable for ______ @ ________
2 days Room temp
371
Methods of Analysis ACP Variables
Room temp Bilirubin Hemolysis Heparin, Oxalate, Fluorides
372
VARIABLES (ACP) Room temp -ACP stable within ________ @ RT because CO2 from blood sample is released which (increases/decreases) pH of the sample
1-2 hrs increases
373
false (decrease/increase) due TRAP/RBC ACP
Bilirubin - decrease Hemolysis - increase
374
Heparin, Oxalate, Fluorides - false (decrease/increase)
decrease
375
in measuring prostatic ALP what is the inhibitor
(L. tartrate -
376
Enumerate the steps in measurign prostatic ACP
1. Measure total ACP 2. Add L-tartrate 3. Measure total ACP (TRAP) ○ Prostatic ACP = Total ACP - TR
377
Enumerate the different kind of ACP methods
1. Gutman and Gutan 2. Shinowara 3. Babson, Read & Philips 4. Roy and Hillman
378
GUTMAN AND GUTAN Substrate
Phenyl phosphate
379
GUTMAN AND GUTAN End product
Inorganic phosphate
380
SHINOWARA Substrate
P-nitrophenylphosphate
381
SHINOWARA End Product
p-nitrophenol
382
Babson, Read & Philips Substrate
α-naphthylphosphate
383
BABSON, READ & PHILIPS End product
α-naphthol
384
ROY AND HILLMAN Substrate
Thymolphthalein monophosphate
385
ROY AND HILLMAN End product
Free thymolphthalein